Can medicines inject the vitamins Amazon is missing?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
3 hours ago
- Economic Times
India's children face health risks as tariff-free British junk food enters market under new FTA
India-Britain FTA, announced on Thursday, will allow tariff-free entry for British food and drink, such as chocolate, gingerbread, sweet biscuits, soft drinks and non-alcoholic beer. Another FTA with four EU nations also indicates that chocolates will be cheaper to enter India. This is bad news for the health of India's children. Cheap Britain-made food products, which are likely to be high in fat/sugar/salt (HFSS), could now flood the Indian market and fuel the rapidly growing market of ultra-processed food products. It means consumption of unhealthy diets would increase when India is grappling with a surge in childhood obesity, diabetes and other diet-related NCDs. Aggressive marketing of HFSS products is fuelling obesity. Between 2006 and 2019, the per-capita consumption of such products rose by nearly 50 times. Earlier this year, Narendra Modi launched an anti-obesity campaign, asking people to reduce oil consumption by 10%. This must now be backed by strong regulation on marketing, including mandatory front-of-pack warning labels on HFSS food products. Further, a clearly worded law must restrict advertisements of HFSS foods. In the 1990s, Mexico signed Nafta with the US. Without safeguards, it led to an explosion of sugary drinks and processed foods, ushering in a wave of obesity and diabetes that haunts the country to this day. Mexican health experts call it their 'Nafta moment'. India can't afford to repeat this regulations are not only focusing on labelling but also on marketing restrictions, especially to protect children. While Britain exports HFSS food products to India, it uses traffic light labels, restricts HFSS marketing, and will enforce a 9 PM TV and online ad ban from October. The EU is strengthening its food labelling and marketing restrictions, especially for children. Britain aims to reduce children's exposure to unhealthy food promotion. Chile, Mexico, Brazil and Israel have implemented strong front-of-pack warning sharp contrast, India has no mandatory warning label, and the food industry enjoys the freedom of advertising, partly because of weak laws that are open to interpretation. Cartoon mascots or health claims on unhealthy food products, sponsorships of school or sporting events by food/drink product companies, and unrestricted celebrity endorsements of HFSS products are common occurrences. This is not just a policy gap, it's an equity why the hesitation in India?The science is clear. The PM has spoken. Yet, regulatory action is still caught between industry resistance and bureaucratic delay. The question isn't whether we can do it, it's whether we will. The Supreme Court has also spoken about food labelling and its glaring gaps as the judges asked: 'You all have grandchildren? What are you feeding them? The packets have no information.'The PM has given a moral nudge. The apex court has given a legal one. The Economic Survey has offered the economic rationale. Technically, GoI's dietary guidelines for Indians make this case strong the country needs the health ministry to act boldly. Because if India doesn't lead on this now, it will be our children who pay the price, bite by bite. The writer is convenor, Nutrition Advocacy in Public Interest (NAPi) (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Can Chyawanprash save Dabur in the age of Shark-Tank startups? Piaggio sues former employee for 'Coldplay' reference on CEO Why Air India could loom large on its biggest rival IndiGo's Q1 results Can medicines inject the vitamins Amazon is missing? How India's oil arbitrage has hit the European sanctions wall Stock Radar: Bajaj Finance breaks out from falling supply trendline; likely to hit fresh highs above Rs 1,000 Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts For investors with patience & cash: 6 large-caps with strong balance sheets & big TAM; and an upside potential of more than 24%
Time of India
4 hours ago
- Time of India
India's 8 Tropic of Cancer States every traveller must explore; from Gujarat to Meghalaya
For those who don't know, the Tropic of Cancer is among the five prime circles of latitude that mark maps of the Earth. In India, the Tropic of Cancer passes through eight Indian states, and it holds a major geographical and climatic importance. The Tropic of Cancer passes through Gujarat (West), Rajasthan (North), Madhya Pradesh (Central), Chhattisgarh (Central), Jharkhand (East), West Bengal (East), Tripura (North East), and Mizoram (North East). Gujarat Not many must be aware of the fact that Gujarat is the entry point of the Tropic of Cancer in India and passes near Amreli and Rajkot. This is the reason why Gujarat's has a hot semi-arid to arid climate. Rajasthan The Tropic of Cancer passes through southern Rajasthan. The line passed through parts of Dungarpur and Banswara districts. These regions experience extreme temperatures. The summers are extremely hot while winters are quite cool. Madhya Pradesh The line crosses through central Madhya Pradesh, including districts such as Ujjain, Ratlam, and Shajapur. The passage of the Tropic contributes to a mix of tropical wet and dry climate zones. Chhattisgarh The Tropic of Cancer passes through northern Chhattisgarh. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo It also crosses Korba and Surguja districts. The region experiences moderate to warm weather conditions. The state also experiences heavy rainfall during the monsoon because of this geographical feature. Jharkhand The Tropic of Cancer enters Jharkhand near Kanke, close to Ranchi. It is a fact that Ranchi is almost exactly on the Tropic of Cancer. This is the reason why the place has a subtropical weather condition. West Bengal The Tropic of Cancer passes through Purulia, Bankura, and Nadia in West Bengal. These regions experience humid subtropical climates. The summer temperatures are extremely high. Tripura The Tropic of Cancer passes through the middle of Tripura. The city of Udaipur is the closest to the Tropic of Cancer in India. It passes exactly through the capital city, Agartala. It is one of the northeastern states with a moist tropical climate. Mizoram The line of Tropic of Cancer passes through another northeastern state which is Mizoram. It crosses through southern Mizoram, influencing the lush hilly terrain and tropical monsoon climate. Despite being close to the tropics, the elevation provides milder temperatures.
Time of India
5 hours ago
- Time of India
Cipla targets $1 bn US revenue in FY27
Mumbai: Cipla aims to achieve $1 billion sales in the US by the next fiscal year, driven by the products it has lined up for launch which the Indian drug maker expects will more than compensate for the imminent patent expiry and price erosion on cancer drug Revlimid. 'We believe our pipeline should get us closer to the target (of $1 billion) or surpass that by FY27, depending on the launch timing,' managing director and global chief executive Umang Vohra said over an investor call on Friday. Explore courses from Top Institutes in Please select course: Select a Course Category Management others Finance Technology MBA Degree PGDM Cybersecurity Project Management Data Science CXO Digital Marketing Design Thinking Product Management healthcare Operations Management Data Science Leadership Data Analytics Public Policy MCA Others Artificial Intelligence Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK GMPBE India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months IIM Kozhikode CERT-IIMK General Management Programme India Starts on undefined Get Details Skills you'll gain: Duration: 9 Months IIM Calcutta CERT-IIMC APSPM India Starts on undefined Get Details 'We have plans for all our launches that are coming in to make up for the revenue losses for Revlimid and that will happen in the short to medium term,' he added. The US remains a very attractive market for Cipla. 'We see it as a growth market over the next 3-5 years,' he said. A generic version of Revlimid (lenalidomide) is one of Cipla's top-selling products in the US. As part of an out of court settlement, Cipla manufactures and markets the drug in the US. Analysts said the expiry of the drug's patent is expected to significantly impact Cipla through a reduction in revenue and potential margin pressure. Cipla has a robust pipeline for the US business with respiratory generic Advair closer to commercialisation and is also preparing for launch of generic Symbicort and a couple of inhalation products. It also plans to launch 2–3 peptide assets in FY26. Timely monetisation of these launches remains critical for the company to offset the lenalidomide generic sales erosion, according to a report by broking firm IIFL. Vohra sees the respiratory segment and new product launches lined up in the category to be the biggest opportunity for Cipla in the next 12 months. 'We have 3-4 launches coming up for the US alone, we have several coming up for emerging markets and several for India,' he told ET. About potential US tariffs on the pharma sector, Vohra said he does not see it having a 'debilitating effect'. There will be an impact, but it will not derail the business, he said. The company on Friday reported a 10% year-on-year increase in consolidated net profit to Rs 1,298 crore for the first quarter ended June. Revenue rose 4% to Rs 6,957 crore and Ebitda was 25.6% of the revenue, the company stated in a filing with stock exchanges. Its India business delivered growth of 6% year-on-year, topping Rs 3,000 crore for the first time ever in a quarter, contributing 44% to the total revenue. Revenue from North America was $226 million (about Rs 1,955 crore) supported by traction in differentiated assets. It launched two generic oncology products in the US in the past quarter: nano paclitaxel vials and nilotinib capsules. 'This performance builds on a strong prior year-on-year quarter where we achieved our highest ever US generics revenue,' said Vohra. Meanwhile, the company has signed an agreement to launch its first biosimilar product in the US that is expected in Q2 FY26. 'We will in-license a few assets through partnerships in the near term and maybe launch our own biosimilar assets around 2029-2030,' Vohra said. The company is betting big on GLP-1, which controls sugar levels and appetite, and sees it as a 'significant growth driver for its business.' 'For us the entire GLP 1 category is important rather than looking at individual categories within that. It will shape up in a manner depending on pipeline assets,' said Vohra. Cipla aims to be among the first wave of launchers for the drugs. The company plans to have a hybrid strategy including having its own products as well as through partnerships.
